Evidence map›Paper›PMID 42544794›Full record

ArticleArchiv der Pharmazie2026

Targeting Human Protein Kinase CK2 by a Library of Indeno[1,2-b]Indoles: Contribution of Thermal Shift Assay to Pre-Screening and Co-Crystallization to Post-Screening.

Matheus M Guimarães, Christian Werner, Belen Leroy, Johana Charles, Jean Guillon, Noël Pinaud, Angélique Mularoni, Marc Jean-Baptiste, Perrine Ximenes, Alexander Gast and 9 more

Abstract read
In one paragraph

Article in Archiv der Pharmazie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Matheus M GuimarãesGastroenterology and Technologies for Health Team, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, CNRS 5286, INSERM 1052, Université Claude Bernard Lyon 1, Univ. Lyon, Lyon, France.ORCID https://orcid.org/0000-0002-0936-4666
Christian WernerInstitute of Biochemistry, Department of Chemistry and Biochemistry, University of Cologne, Koln, Germany.ORCID https://orcid.org/0000-0001-5263-4994
Belen LeroyGastroenterology and Technologies for Health Team, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, CNRS 5286, INSERM 1052, Université Claude Bernard Lyon 1, Univ. Lyon, Lyon, France.ORCID https://orcid.org/0009-0003-3437-0894
Johana CharlesGastroenterology and Technologies for Health Team, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, CNRS 5286, INSERM 1052, Université Claude Bernard Lyon 1, Univ. Lyon, Lyon, France.
Jean GuillonINSERM, CNRS, ARNA, U1212, UMR 5320, UFR des Sciences Pharmaceutiques, Univ. Bordeaux, Bordeaux, France.
Noël PinaudISM-CNRS UMR 5255, Univ. Bordeaux, Talence, France.ORCID https://orcid.org/0000-0001-7646-5312
Angélique MularoniGastroenterology and Technologies for Health Team, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, CNRS 5286, INSERM 1052, Université Claude Bernard Lyon 1, Univ. Lyon, Lyon, France.
Marc Jean-BaptisteGastroenterology and Technologies for Health Team, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, CNRS 5286, INSERM 1052, Université Claude Bernard Lyon 1, Univ. Lyon, Lyon, France.ORCID https://orcid.org/0000-0002-9628-8111
Perrine XimenesGastroenterology and Technologies for Health Team, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, CNRS 5286, INSERM 1052, Université Claude Bernard Lyon 1, Univ. Lyon, Lyon, France.ORCID https://orcid.org/0009-0005-2862-2279
Alexander GastInstitute of Pharmaceutical and Medicinal Chemistry, PharmaCampus, University of Münster, Münster, Germany.
Helge PrinzInstitute of Pharmaceutical and Medicinal Chemistry, PharmaCampus, University of Münster, Münster, Germany.
Dagmar AicheleInstitute of Pharmaceutical and Medicinal Chemistry, PharmaCampus, University of Münster, Münster, Germany.ORCID https://orcid.org/0000-0001-5937-0450
Alan G GonçalvesLaboratory of Synthesis of Heterocycles and Glycoconjugates, Pharmaceutical Sciences Post-Graduation Program, Federal University of Paraná, Curitiba, Paraná, Brazil.
Christelle MarminonGastroenterology and Technologies for Health Team, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, CNRS 5286, INSERM 1052, Université Claude Bernard Lyon 1, Univ. Lyon, Lyon, France.
Zouhair BouazizInstitut des Sciences Pharmaceutiques et Biologiques (ISPB), Faculté de Pharmacie, Université Claude Bernard Lyon 1, Univ. Lyon, Lyon, France.
Joachim JoseInstitute of Pharmaceutical and Medicinal Chemistry, PharmaCampus, University of Münster, Münster, Germany.ORCID https://orcid.org/0000-0002-0666-2676
Jean-Guy DelcrosGastroenterology and Technologies for Health Team, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, CNRS 5286, INSERM 1052, Université Claude Bernard Lyon 1, Univ. Lyon, Lyon, France.ORCID https://orcid.org/0000-0002-9593-4046
Karsten NiefindInstitute of Biochemistry, Department of Chemistry and Biochemistry, University of Cologne, Koln, Germany.ORCID https://orcid.org/0000-0002-0183-6315
Marc Le BorgneGastroenterology and Technologies for Health Team, Centre de Recherche en Cancérologie de Lyon, Centre Léon Bérard, CNRS 5286, INSERM 1052, Université Claude Bernard Lyon 1, Univ. Lyon, Lyon, France.ORCID https://orcid.org/0000-0003-1398-075X

Funding

Agence Nationale de la Recherche (ANR) ANR-22-CE92-0081-01CAPES PrInt UFPR Program 88887.370799/2019-00CAPES PrInt UFPR Program CAPES Finance Code 001Deutsche Forschungsgemeinschaft (DFG) JO 183/10-1Deutsche Forschungsgemeinschaft (DFG) NI 643/11-1Deutsche Forschungsgemeinschaft (DFG) NI 643/4-2Institut Convergence PLAsCAN ANR-17-CONV-0002
6 · The paper itself

Abstract

Protein kinase CK2 is the subject of numerous studies in medicinal chemistry due to its involvement in the development of several diseases, primarily cancers. Its overexpression in tumor cells is related to key processes such as tumor immune evasion and cell proliferation. The scientific approach of this study aims to investigate the thermal shift assay (TSA) as a pre-screening tool and to complement it with a co-crystallization approach in post-screening. Therefore, the synthesis of seven small-molecule CK2 inhibitors derived from indeno[1,2-b]indoles was supplemented by 18 related derivatives from our in-house compound library. The 25 molecules belong to four sub-scaffolds, namely 4b,9b-dihydroxy-4b,5,6,7,8,9b-hexahydroindeno[1,2-b]indole-9,10-dione (D-0), 5,6,7,8-tetrahydroindeno[1,2-b]indole-9,10-dione (D-1), 9-hydroxy-5H-indeno[1,2-b]indol-10-one (D-2), and 5H-indeno[1,2-b]indole-6,9,10-trione (D-3). The most active CK2 inhibitors identified by capillary electrophoresis (CE)-based assay belong to the D-1 sub-scaffold. In the TSA, these compounds also generate significant shifts of the melting temperature (Tm) of CK2, indicating a clear correlation between the results of the CE-based assay and those of the TSA. The contribution of co-crystallization in post-screening also demonstrated the effectiveness of D-1 sub-scaffold compared with D-0 sub-scaffold.

Indexed as

Casein Kinase IIIndenesIndolesProtein Kinase InhibitorsSmall Molecule LibrariesCrystallizationDose-Response Relationship, DrugHumansMolecular StructureStructure-Activity RelationshipCasein Kinase IIIndenesIndolesProtein Kinase InhibitorsSmall Molecule Librariescapillary electrophoresisindeno[1,2‐b]indoleprotein kinase CK2structural analysisthermal shift assay

Identifiers

PMID42544794
PMCPMC13430583

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.